Why is there so much enthusiasm if there are no human trials?

The animal data is genuinely impressive, and plausible reasoning explains the absence of trials: these are short peptides with limited patent protection, so nobody can recoup the cost of a trial programme. But 'no trial because no profit' is an explanation for the gap, not a substitute for filling it.

Is the cancer risk real?

It is theoretical rather than demonstrated — no study has shown these compounds cause cancer. The concern is mechanistic and reasonable: promoting angiogenesis and cell migration is the same thing tumours do to spread. With no long-term human data either way, the caution is warranted.

The nerve repair stack

This is the most popular peptide stack on the internet and the one with the widest gap between enthusiasm and human evidence. The animal literature is genuinely substantial. The human trial literature is essentially empty.

The bottleneck

Peripheral nerve and connective tissue repair, which is slow, angiogenesis-dependent and substrate-limited.

What is in it, and why

BPC-157Evidence grade: Animal studies only
Angiogenesis and tissue healing across tendon, muscle, gut and peripheral nerve in rodent models.
Timing: Daily, often subcutaneously near the injury site in community protocols.
TB-500Evidence grade: Animal studies only
Cell migration. Repair requires cells to reach the site, and this is the mechanism BPC-157 does not cover.
Timing: Twice weekly during a loading phase — longer-acting than BPC-157.
GHK-CuEvidence grade: Early human data
Collagen synthesis and remodelling, with the strongest human evidence of the three — but that evidence is topical.
Timing: Topical for skin; systemic use has no human dose reference.

Why these go together

BPC-157 and TB-500 cover different repair stages — blood supply and cell migration — which is the actual reason they are paired so often.
GHK-Cu adds the remodelling phase, where new collagen is organised rather than merely deposited.

Conflicts and risks

Consider this

All three carry a theoretical cancer concern. Angiogenesis, cell migration and growth signalling are exactly what a tumour needs. Anyone with a personal or family cancer history should treat this as a hard stop.

Consider this

BPC-157 and TB-500 are both banned by WADA — a competitive athlete testing positive faces a real sanction.

Consider this

GHK-Cu is absolutely contraindicated in Wilson's disease and any copper metabolism disorder.

Consider this

None of the three has a published human efficacy trial for musculoskeletal repair.

The practice protocol

This half is not optional. It shares the mechanism, and it usually has the better evidence.

1.Progressive tissue loading under a physiotherapist. Unloaded tendon does not remodel properly regardless of what you inject.
2.Prioritise deep sleep — growth hormone pulses and most tissue repair happen there.
3.Slow exhale-weighted breathing: the vagus is itself a peripheral nerve, and pain drives sympathetic tone that works against recovery.

Nutrition and sleep foundations

These gate everything above them. A stack running on five hours of sleep and insufficient protein is mostly an expensive placebo.

Protein at 1.6–2.2g/kg. Repair is substrate-limited before it is signal-limited.
Vitamin C, required as a cofactor for collagen synthesis.
Adequate total calories — the body deprioritises repair in a deficit.
B12 status specifically, if nerve symptoms are present.

The evidence ceiling

Zero published human RCTs for BPC-157 or TB-500. The GHK-Cu human evidence is dermatological and topical. Everything else is rodent work. That is the honest ceiling and it should carry real weight in the decision.

Common questions

: The animal data is genuinely impressive, and plausible reasoning explains the absence of trials: these are short peptides with limited patent protection, so nobody can recoup the cost of a trial programme. But 'no trial because no profit' is an explanation for the gap, not a substitute for filling it.
: It is theoretical rather than demonstrated — no study has shown these compounds cause cancer. The concern is mechanistic and reasonable: promoting angiogenesis and cell migration is the same thing tumours do to spread. With no long-term human data either way, the caution is warranted.